Kekre N, Connors JM. Venous thromboembolism incidence in hematologic malignancies. Blood Rev. 2019;33:24–32.

Article  PubMed  Google Scholar 

Blom JW, Doggen CJM, Osanto S, Rosendaal FR. Malignancies, prothrombotic mutations, and the risk of venous thrombosis. JAMA. 2005;293(6):715–22.

Article  PubMed  Google Scholar 

Behranwala KA, Williamson RCN. Cancer-associated venous thrombosis in the surgical setting. Ann Surg. 2009;249(3):366–75.

Article  PubMed  Google Scholar 

Kiracı ZK, Yalçın N, Cennet Ö, Demirkan K, Yorgancı K. Education and clinical pharmacist-led management strategies for the risk and prophylaxis of venous thromboembolism in general surgery. Thromb J. 2023;21(1):86.

Article  PubMed  PubMed Central  Google Scholar 

Becattini C, Pace U, Pirozzi F, et al. Rivaroxaban vs placebo for extended antithrombotic prophylaxis after laparoscopic surgery for colorectal cancer. Blood. 2022;140(8):900–8.

Article  PubMed  PubMed Central  Google Scholar 

Young AM, Marshall A, Thirlwall J, et al. Comparison of an Oral Factor Xa Inhibitor With Low Molecular Weight Heparin in Patients With Cancer With Venous Thromboembolism: Results of a Randomized Trial (SELECT-D). J Clin Oncol. 2018;36(20):2017–23.

Article  PubMed  Google Scholar 

Khorana AA, McCrae KR, Milentijevic D, et al. Current practice patterns and patient persistence with anticoagulant treatments for cancer-associated thrombosis. Res Pract Thromb Haemost. 2017;1(1):14–22.

Article  PubMed  PubMed Central  Google Scholar 

Schulman S, Kearon C. Definition of major bleeding in clinical investigations of antihemostatic medicinal products in non-surgical patients. J Thromb Haemost. 2005;3(4):692–4.

Article  PubMed  Google Scholar 

Felder S, Rasmussen MS, King R, et al. Prolonged thromboprophylaxis with low molecular weight heparin for abdominal or pelvic surgery. Cochrane Database Syst Rev. 2019;8(8):Cd004318.

PubMed  Google Scholar 

Knoll W, Fergusson N, Ivankovic V, et al. Extended thromboprophylaxis following major abdominal/pelvic cancer-related surgery: a systematic review and meta-analysis of the literature. Thromb Res. 2021;204:114–22.

Article  PubMed  Google Scholar 

Ross ME, Glickman A, Brennecke A, Tayebnejad A, Guntupalli SR. Adherence to postoperative thromboprophylactic medication among gynecologic oncology patients: a subanalysis. Gynecol Oncol. 2020;158(3):754–9.

Article  PubMed  Google Scholar 

Schrag D, Uno H, Rosovsky R, et al. Direct oral anticoagulants vs low-molecular-weight heparin and recurrent VTE in patients with cancer: a randomized clinical trial. JAMA. 2023;329(22):1924–33.

Article  PubMed  PubMed Central  Google Scholar 

Planquette B, Bertoletti L, Charles-Nelson A, et al. Rivaroxaban vs dalteparin in cancer-associated thromboembolism: a randomized trial. Chest. 2022;161(3):781–90.

Article  PubMed  Google Scholar 

McBane RD 2nd, Wysokinski WE, Le-Rademacher JG, et al. Apixaban and dalteparin in active malignancy-associated venous thromboembolism: the ADAM VTE trial. J Thromb Haemost. 2020;18(2):411–21.

Article  PubMed  Google Scholar 

Agnelli G, Becattini C, Meyer G, et al. Apixaban for the treatment of venous thromboembolism associated with cancer. N Engl J Med. 2020;382(17):1599–607.

Article  PubMed  Google Scholar 

Raskob GE, van Es N, Verhamme P, et al. Edoxaban for the treatment of cancer-associated venous thromboembolism. N Engl J Med. 2018;378(7):615–24.

Article  PubMed  Google Scholar 

Key NS, Khorana AA, Kuderer NM, et al. Venous thromboembolism prophylaxis and treatment in patients with cancer: ASCO guideline update. J Clin Oncol. 2023;41(16):3063–71.

Article  PubMed  Google Scholar 

Falanga A, Ay C, Di Nisio M, et al. Venous thromboembolism in cancer patients: ESMO Clinical Practice Guideline. Ann Oncol. 2023;34(5):452–67.

Article  PubMed  Google Scholar 

Farge D, Frere C, Connors JM, et al. 2022 international clinical practice guidelines for the treatment and prophylaxis of venous thromboembolism in patients with cancer, including patients with COVID-19. Lancet Oncol. 2022;23(7):e334–47.

Article  PubMed  PubMed Central  Google Scholar 

Lyman GH, Carrier M, Ay C, et al. American Society of Hematology 2021 guidelines for management of venous thromboembolism: prevention and treatment in patients with cancer. Blood Adv. 2021;5(4):927–74.

Article  PubMed  PubMed Central  Google Scholar 

Guntupalli SR, Brennecke A, Behbakht K, et al. Safety and efficacy of apixaban vs enoxaparin for preventing postoperative venous thromboembolism in women undergoing surgery for gynecologic malignant neoplasm: a randomized clinical trial. JAMA Netw Open. 2020;3(6):e207410.

Article  PubMed  PubMed Central  Google Scholar 

Longo de Oliveira ALM, de Oliveira Pereira RF, Agati LB, et al. Rivaroxaban versus enoxaparin for thromboprophylaxis after major gynecological cancer surgery: the VALERIA Trial: Venous thromboembolism prophylAxis after gynecoLogical pElvic cancer surgery with RIvaroxaban versus enoxAparin (VALERIA trial). Clin Appl Thromb Hemost. 2022;28:10760296221132556.

Article  PubMed  PubMed Central  Google Scholar 

Page MJ, McKenzie JE, Bossuyt PM, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. Int J Surg (London, England). 2021;88:105906.

Article  Google Scholar 

Shea BJ, Reeves BC, Wells G, et al. AMSTAR 2: a critical appraisal tool for systematic reviews that include randomised or non-randomised studies of healthcare interventions, or both. BMJ (Clinical research ed). 2017;358:j4008.

Article  PubMed  Google Scholar 

Kaatz S, Ahmad D, Spyropoulos AC, Schulman S. Definition of clinically relevant non-major bleeding in studies of anticoagulants in atrial fibrillation and venous thromboembolic disease in non-surgical patients: communication from the SSC of the ISTH. J Thromb Haemost. 2015;13(11):2119–26.

Article  PubMed  Google Scholar 

Sterne JAC, Savović J, Page MJ, et al. RoB 2: a revised tool for assessing risk of bias in randomised trials. BMJ (Clinical Research ed). 2019;366:l4898.

PubMed  Google Scholar 

Sterne JA, Hernán MA, Reeves BC, et al. ROBINS-I: a tool for assessing risk of bias in non-randomised studies of interventions. BMJ (Clinical research ed). 2016;355:i4919.

PubMed  Google Scholar 

DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials. 1986;7(3):177–88.

Article  PubMed  Google Scholar 

Higgins JPT, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ (Clinical research ed). 2003;327(7414):557–60.

Article  PubMed  Google Scholar 

Egger M, Davey Smith G, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. BMJ (Clinical research ed). 1997;315(7109):629–34.

Article  PubMed  Google Scholar 

Haddaway NR, Page MJ, Pritchard CC, McGuinness LA. PRISMA2020: an R package and Shiny app for producing PRISMA 2020-compliant flow diagrams, with interactivity for optimised digital transparency and Open Synthesis. Campbell Syst Rev. 2022;18(2):e1230.

Article  PubMed  PubMed Central  Google Scholar 

Zhao M, Bao Y, Jiang C, et al. Rivaroxaban versus nadroparin for thromboprophylaxis following thoracic surgery for lung cancer: a randomized, noninferiority trial. Am J Hematol. 2023;98(8):1185–95.

Article  PubMed  Google Scholar 

Nagy A, Tegge AN, Borden LE, Osborne JL, Valea FA, Iglesias DA. A retrospective comparison of oral rivaroxaban versus subcutaneous low-molecular-weight heparin for postoperative thromboprophylaxis in women with a gynecologic malignancy. Gynecol Oncol. 2018;149:199–200.

Article  Google Scholar 

Ortiz RM, Golijanin B, O’Rourke TK, et al. Direct oral anticoagulants for venous thromboembolism prophylaxis following robot-assisted radical cystectomy: a retrospective feasibility study at a single academic medical center. Urology. 2021;156:154–62.

Article  PubMed  Google Scholar 

Rashid MF, Jackson TL, Morgan JA, et al. Dabigatran (Pradaxa) is safe for extended venous thromboembolism prophylaxis after surgery for pancreatic cancer. J Gastrointest Surg. 2019;23(6):1166–71.

Article  PubMed  Google Scholar 

Rich JM, Elkun Y, Geduldig J, et al. Outcomes from a prospectively implemented protocol using apixaban after robotic radical cystectomy. BJU Int. 2023;132:390.

Article  PubMed  Google Scholar 

Spénard E, Geerts W, Lin Y, et al. Apixaban for extended postoperative thromboprophylaxis in gynecologic oncology patients undergoing laparotomy. Gynecol Oncol. 2023;172:9–14.

Article  PubMed  Google Scholar 

Swaroop M, Borden L, Locklear T, et al. Postoperative thromboprophylaxis with oral rivaroxaban versus subcutaneous low-molecular-weight heparin: a retrospective comparison in women with a gynecologic malignancy. Gynecol Oncol. 2021;162:S239.

Article  Google Scholar 

Westerman ME, Bree KK, Msaouel P, et al. Apixaban vs enoxaparin for post-surgical extended-duration venous thromboembolic event prophylaxis: a prospective quality improvement study. J Urol. 2022;208(4):886–95.

Article  PubMed  Google Scholar 

McGuinness LA, Higgins JPT. Risk-of-bias VISualization (robvis): An R package and Shiny web app for visualizing risk-of-bias assessments. Res Synth Methods. 2021;12(1):55–61.

Article  PubMed  Google Scholar 

Merkow RP, Bilimoria KY, McCarter MD, et al. Post-discharge venous thromboembolism after cancer surgery: extending the case for extended prophylaxis. Ann Surg. 2011;254(1):131–7.

Article